【肺癌】「eyonis™ LCS SaMD」 利用LDCT篩檢「肺癌」準確率超越監管許可設定

 【肺癌】「eyonis™ LCS SaMD」 利用低劑量電腦斷層掃描(LDCT)篩檢「肺癌」準確率超越監管許可設定

 文章出處  

Businesswire 

 

 原文標題  

Median Technologies Announces Pivotal REALITY Study of Its eyonis™ LCS Lung Cancer Diagnostic Met All Primary and Secondary Endpoints 

 

 Twitter  

https://x.com/aimedadviser/status/1830381684304535774 

 

 文章序號  

6197 

 

智醫科學－AI醫療技術、應用與市場動態

Copyright ©2024 智醫科學 MEDai.tw All rights reserved.

The content of this site is intended for healthcare and medical professionals.